GlassScriptPhysician profile
Heidi J Roppelt
NPI 1578588703
$16,368.09
in general payments reported to CMS, 2019-2025
26 companies · $768 in 2025
The $768 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,815 · 2020: $1,472 · 2021: $2,972 · 2022: $675 · 2023: $850 · 2024: $817 · 2025: $768.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,335 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,334.58 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $12,410.87 | 2019-2024 | Rinvoq, Skyrizi, Teflaro |
| Amgen INC. | $1,133.03 | 2019-2025 | Krystexxa, Enbrel, Evenity |
| Janssen Biotech, INC. | $693.51 | 2019-2025 | Tremfya |
| Pfizer INC. | $626.16 | 2019-2025 | |
| Lilly USA, LLC | $371.06 | 2019-2024 | Taltz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $130.89 | 2021-2025 | Cyltezo, Jardiance |
| Glaxosmithkline, LLC. | $122.92 | 2019-2024 | Benlysta |
| Astrazeneca Pharmaceuticals LP | $121.67 | 2021-2023 | Saphnelo |
| Genentech USA, INC. | $116.58 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $98.40 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $79.82 | 2020-2021 | |
| Radius Health, INC. | $60.62 | 2022-2023 | Tymlos |
| Janssen Pharmaceuticals, INC | $55.16 | 2021-2025 | Tremfya |
| Sandoz INC. | $47.10 | 2023-2024 | Hyrimoz |
| Harmony Biosciences LLC | $39.34 | 2024 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $39.23 | 2019 | |
| Ucb, INC. | $39.03 | 2019 | |
| Opko Pharmaceuticals, LLC | $29.65 | 2019 | |
| Integra Lifesciences Corporation | $27.01 | 2023 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Alexion Pharmaceuticals, INC. | $22.67 | 2025 | Strensiq |
| Jazz Pharmaceuticals INC. | $22.32 | 2022 | |
| Horizon Therapeutics Plc | $19.84 | 2021 | |
| Octapharma USA, INC. | $16.82 | 2024 | Octagam Immune Globulin (Human) |
| Biocomposites INC | $15.52 | 2024 | |
| Genzyme Corporation | $14.45 | 2025 | |
| Kaleo, INC. | $14.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heidi Roppelt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.